dacomitinib

Dacomitinib is an oral, irreversible small molecule tyrosine kinase inhibitor that targets the human epidermal growth factor receptor (EGFR) family, specifically EGFR (HER1), HER2, and HER4. It covalently binds to cysteine residues in the catalytic domains of these receptors, leading to sustained inhibition of their kinase activity. Dacomitinib is primarily indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations—namely exon 19 deletion or exon 21 L858R substitution—as detected by an FDA-approved test. By blocking aberrant signaling through these mutated receptors, dacomitinib slows or halts tumor cell proliferation and survival[1][3][7][10]. The drug was developed by Pfizer in collaboration with SFJ Pharmaceuticals[10].

Brand names

Vizimpro

Other names

dacomitinib monohydrate